Epizyme to partner with Foundation Medicine for tazemetostat trial

Epizyme Inc. has agreed to a partnership with Foundation Medicine to identify and enroll support patients for the upcoming Phase 2 trial of tazemetostat on patients who have non-Hodgkin lymphoma (NHL).

“This agreement exemplifies our commitment to execute enrollment in our ongoing Phase 2 NHL study, particularly patients with EZH2 mutations,” Epizyme President and CEO Robert Bazemore said. “We are pleased to partner with Foundation Medicine, an industry leader and innovator in molecular information and comprehensive genomic profiling, to advance our tazemetostat clinical program and accelerate identification of patients who may benefit from this therapy.”

To identify a population of people who have NHL, Epizyme will incorporate Foundation Medicine’s SmartTrials Precision Enrollment Program as well as FoundationOne Heme panel. The search will be specified to include NHL patients who have EZH2 mutations and constitute specific cohorts.

Tazemetostat was developed by Epizyme as its first-in-class oral EZH2 inhibitor, which is being studied in ongoing trials. Early data from these trials has shown encouraging results.